AI-generated content for informational purposes only. Not financial advice. Always do your own research.

حول

Global leader in cloud-connected medical devices for sleep apnea and respiratory care, treating over 160 million patients. Software-driven digital health platform.

أسهم الشيخوخة السكانية

ResMed هي الرائدة العالمية في الأجهزة المتصلة بالسحابة لعلاج انقطاع التنفس أثناء النوم والرعاية التنفسية، وتعالج أكثر من 160 مليون مريض وتستفيد من الطلب الناجم عن شيخوخة السكان على العلاج التنفسي.

Key Financials RMD

السعر $252.55
التغيير (1 يوم) +2.78%
التغيير (30D) +4.85%
التغيير (60D) +3.20%
التغيير (90D) -10.25%
التغيير (180D) +3.18%
التغيير (1Y) +6.74%
التغيير (5Y) +26.36%
P/E Ratio 32.09
EPS (TTM) $7.87
نطاق 52 أسبوعاً $199.92 — $293.81
50-Day MA $252.89
الحجم 971.0K

Data updated Feb 15 · Source: Twelve Data

4.3
1 reviews
Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Claude Opus 4.6
AI Review
4.3/5

ResMed is a global leader in sleep apnea and respiratory care devices, positioning it squarely as a beneficiary of aging population demographics. As the elderly population grows, demand for CPAP devices, ventilators, and connected health solutions should expand meaningfully over the coming decades.

Financially, ResMed trades at a P/E of 32x with EPS of $7.87, reflecting a premium valuation justified by its dominant market position and recurring revenue from masks and accessories. The stock sits near its 50-day moving average at ~$253, well off its 52-week high of $294, suggesting potential upside if sentiment improves.

Bull case: Massive underpenetrated sleep apnea market, strong recurring revenue model, digital health integration through myAir and AirView platforms, and demographic tailwinds from aging populations globally. Bear case: GLP-1 weight-loss drugs (Ozempic/Wegovy) could reduce sleep apnea prevalence, competitive pressure from Philips' market re-entry, and the premium valuation leaves limited margin for error. The 90-day decline of -10.25% likely reflects lingering GLP-1 concerns. Despite this overhang, ResMed's fundamentals and demographic positioning remain compelling for long-term investors.

Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Feb 15, 2026
ResMed Screenshot

Added: Feb 15, 2026

resmed.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

كيفية اختبار استراتيجية التداول بأثر رجعي: الطرق والأخطاء الشائعة وما تعنيه النتائج فعلاً

كيفية اختبار استراتيجية التداول بأثر رجعي: الطرق والأخطاء الشائعة وما تعنيه النتائج فعلاً

كل متداول لديه استراتيجية تبدو رائعة في رأسه. الاختبار بأثر رجعي هو كيفية معرفتك ما إذا كانت تعمل فعلاً. إليك كيفية اختبار الاستراتيجيات بشكل صحيح والمقاييس التي تهم وسبب أن معظم نتائج الاختبار بأثر رجعي جيدة جداً لتكون حقيقية.